Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for t...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

MattressMonkey007 Aug. 18 at 7:46 PM

$PHAT … looks like I add some shares this Friday. Thanks for the juicy premium and the shares. Forward.

0 · Reply

Valueforall Aug. 18 at 6:19 PM

$PHAT I still love 💕 you when you suck you pretty hot and tempting POS 😂

1 · Reply

longshot45 Aug. 17 at 8:13 PM

$PHAT There was a nice 10:52 AM buy today

0 · Reply

anachartanalyst Aug. 17 at 6:02 PM

$PHAT https://anachart.com/wp-content/uploads/2026/08/1786989708_soc-img.jpg

0 · Reply

fgggggggg Aug. 17 at 3:56 PM

$PHAT

0 · Reply

Pelle1966 Aug. 17 at 10:02 AM

$NUAI Soon to the Moon => $50 +++ $PHAT $GPUS $MSFT $SPCX

0 · Reply

Valueforall Aug. 16 at 7:12 PM

$PHAT The Reality Disconnect: Daily maintenance dosing is only half the market. Unlocking a validated, fast-acting PRN label creates a massive "lifestyle drug" paradigm shift in gastroenterology, expanding their total addressable market (TAM) exponentially while securing extended regulatory exclusivity pathways. 🔥 $PHAT — Shorts are treating Phathom like an un-funded clinical sandbox, completely ignoring that $VOQUEZNA generated $74.3M in Q2 2026 alone while crossing into non-GAAP operating profitability! You are looking at a first-in-class PCAB monopoly displacing 30-year-old PPI generics with 1.7M+ scripts written—when short algorithms (~18% short float) realize the debt is covered by real commercial cash flow, the violent squeeze upward toward analyst price targets ($22–$30+) will be unstoppable. 🧬💎

1 · Reply

longshot45 Aug. 16 at 2:41 PM

$PHAT Get ready for a Goldman upgrade folks. Paul Choi rated us ’neutral’ on 5/2/25 and Goldmans 13fs shows they held 192,526 as of 6/30/25. The most recent 13f shows they bumped their holdings to 1,778,032… not feeling so neutral anymore lol

1 · Reply

OnlyFibs Aug. 16 at 1:31 AM

$PHAT | Phathom Pharmaceuticals | Healthcare 💊 High-conviction bid volume is building on $PHAT as price tightens right above primary volume profile demand! 💥 Strong buyer response off the $8.85 demand sweep confirms solid floor defense following the pullback ⚡ Profitability & Fundamentals: High-growth biopharmaceutical company scaling VOQUEZNA sales across erosive GERD and H. pylori treatment markets. Technicals: 1w timeframe shows a bullish triple bottom base structure holding firm above baseline support 📊 Stochastic RSI is turning upward off oversold levels. Holding $8.85 maintains the reversal base. Bull Key Levels: $9.58 🐂 🔥 | Confirm: $10.01 🐂 📈 | Extension: $12.91 🐂 🚀 Bear Key Levels: $8.85 🐻 ⚠️ | Confirm: $6.50 🐻 🚨 | Extension: $4.00 🐻 📉 Stop Loss: $8.50 🛑 Targets: $12.91 / $15.98 💰 🍺 OVERALL: 🐂 BULLISH 🐂 #PHAT #optionsflow #stockmarket #technicalanalysis #swingtrading #hovdid

0 · Reply

Fire7878 Aug. 14 at 11:55 PM

$PHAT stock dropped 300m (30%) in MC due to a 10m dollar reduction in end of year guidance. Essentially a rounding error of <3% of thier expected sales in 2026.

1 · Reply

Phathom Pharmaceuticals price target lowered to $14 from $18 at Barclays

2026-07-31T13:31:05.000Z - 18 days ago

Phathom Pharmaceuticals price target lowered to $20 from $22 at Craig-Hallum

2026-07-31T12:59:22.000Z - 19 days ago

Phathom Pharmaceuticals price target lowered to $21 from $28 at Raymond James

2026-07-31T11:01:13.000Z - 19 days ago

Phathom Pharmaceuticals price target lowered to $22 from $25 at Guggenheim

2026-07-30T19:20:38.000Z - 19 days ago

Phathom Pharmaceuticals price target lowered to $22 from $28 at Needham

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Phathom Pharmaceuticals Earnings release: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Phathom Pharmaceuticals Quarterly report: Q2 2026

Jul 30, 2026, 8:00 AM EDT - 20 days ago

Phathom Pharmaceuticals Slides: Q2 2026

2026-07-30T11:36:12.000Z - 20 days ago

Phathom Pharmaceuticals reports Q2 non-GAAP EPS 0c, consensus (9c)

2026-07-30T11:35:23.000Z - 20 days ago

Phathom Pharmaceuticals lowers FY26 revenue view to $310M-$325M from $320M-$345M

Jul 30, 2026, 7:00 AM EDT - 20 days ago

Phathom Pharmaceuticals Slides: Corporate presentation

Jul 30, 2026, 6:59 AM EDT - 20 days ago

Phathom Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Jul 20, 2026, 8:00 AM EDT - 4 weeks ago

Phathom Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide Business Update on Thursday, July 30, 2026

2026-06-23T12:51:30.000Z - 2 months ago

Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial

Jun 23, 2026, 7:59 AM EDT - 2 months ago

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Jun 9, 2026, 2:40 PM EDT - 2 months ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 3, 2026, 12:15 PM EDT - 2 months ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

2026-05-26T19:00:09.000Z - 3 months ago

Needham pharmaceuticals analysts hold analyst/industry conference call

May 22, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

May 20, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting

May 1, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting

2026-04-30T12:05:31.000Z - 3 months ago

Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)

2026-04-30T12:02:20.000Z - 3 months ago

Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Earnings release: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Quarterly report: Q1 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Phathom Pharmaceuticals Slides: Q1 2026

Apr 30, 2026, 6:59 AM EDT - 3 months ago

Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

Apr 20, 2026, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026

Apr 15, 2026, 1:30 PM EDT - 4 months ago

Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals Proxy statement: Proxy filing

2026-03-27T09:00:23.000Z - 5 months ago

Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

2026-03-23T18:25:38.000Z - 5 months ago

Phathom Pharmaceuticals management to meet with Cantor

Mar 11, 2026, 3:30 PM EDT - 5 months ago

Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 2, 2026, 10:30 AM EST - 6 months ago

Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T12:39:13.000Z - 6 months ago

Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim

2026-02-26T23:40:20.000Z - 6 months ago

Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs

Feb 26, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals Slides: Q4 2025

2026-02-26T12:06:11.000Z - 6 months ago

Phathom Pharmaceuticals reports Q4 EPS (8c), consensus (19c)

2026-02-26T12:05:14.000Z - 6 months ago

Phathom Pharmaceuticals sees FY26 net revenues $320M9$345M, consensus $312.56M

Feb 26, 2026, 7:00 AM EST - 6 months ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Feb 17, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 12, 2026, 11:30 AM EST - 6 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 5, 2026, 8:00 AM EST - 6 months ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

2026-01-08T11:31:01.000Z - 7 months ago

Phathom Pharmaceuticals 6.875M share Secondary priced at $16.00

Jan 7, 2026, 10:33 PM EST - 7 months ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 7 months ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 7 months ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Jan 7, 2026, 7:00 AM EST - 8 months ago

Phathom Pharmaceuticals Slides: Corporate presentation

Dec 2, 2025, 3:25 PM EST - 9 months ago

Phathom Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 18, 2025, 9:30 AM EST - 9 months ago

Phathom Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 12, 2025, 4:40 PM EST - 9 months ago

Phathom Pharmaceuticals Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 3:00 PM EST - 10 months ago

Phathom Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 10 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Quarterly report: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Earnings release: Q3 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Slides: Q3 2025

Oct 30, 2025, 7:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 10 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Sep 8, 2025, 1:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:10 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Cantor Global Healthcare Conference 2025

Aug 20, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 6:59 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jul 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Jun 23, 2025, 4:15 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

Jun 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 11, 2025, 10:40 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 6, 2025, 12:27 PM EDT - 1 year ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

Jun 5, 2025, 9:55 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 3, 2025, 11:30 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: AGM 2025

May 20, 2025, 4:00 PM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Earnings release: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q1 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Q1 2025

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

May 1, 2025, 7:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Apr 28, 2025, 7:59 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 8, 2025, 10:15 AM EDT - 1 year ago

Phathom Pharmaceuticals Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 1 year ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Annual report: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q4 2024

Mar 6, 2025, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q4 2024

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Feb 6, 2025, 10:00 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim SMID Cap Biotech Conference

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 12:00 PM EST - 1 year ago

Phathom Pharmaceuticals Slides: Corporate Presentation

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Dec 3, 2024, 2:10 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 18, 2024, 1:15 PM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Stifel 2024 Healthcare Conference

Nov 12, 2024, 9:30 AM EST - 1 year ago

Phathom Pharmaceuticals Transcript: Guggenheim’s Inaugural Healthcare Innovation Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Phathom Pharmaceuticals Slides: Q3 2024

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Sep 9, 2024, 12:00 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: H.C. Wainwright 26th Annual Global Investment Conference 2024

Aug 19, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 11, 2024, 2:40 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Goldman Sachs 45th Annual Global Healthcare Conference

Jun 5, 2024, 12:30 PM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference

May 23, 2024, 10:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: AGM 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Quarterly report: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Earnings release: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Slides: Q1 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 12, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals Proxy statement: Proxy Filing

Apr 10, 2024, 9:30 AM EDT - 2 years ago

Phathom Pharmaceuticals Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Phathom Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

MattressMonkey007 Aug. 18 at 7:46 PM

$PHAT … looks like I add some shares this Friday. Thanks for the juicy premium and the shares. Forward.

0 · Reply

Valueforall Aug. 18 at 6:19 PM

$PHAT I still love 💕 you when you suck you pretty hot and tempting POS 😂

1 · Reply

longshot45 Aug. 17 at 8:13 PM

$PHAT There was a nice 10:52 AM buy today

0 · Reply

anachartanalyst Aug. 17 at 6:02 PM

$PHAT https://anachart.com/wp-content/uploads/2026/08/1786989708_soc-img.jpg

0 · Reply

fgggggggg Aug. 17 at 3:56 PM

$PHAT

0 · Reply

Pelle1966 Aug. 17 at 10:02 AM

$NUAI Soon to the Moon => $50 +++ $PHAT $GPUS $MSFT $SPCX

0 · Reply

Valueforall Aug. 16 at 7:12 PM

1 · Reply

longshot45 Aug. 16 at 2:41 PM

1 · Reply

OnlyFibs Aug. 16 at 1:31 AM

0 · Reply

Fire7878 Aug. 14 at 11:55 PM

$PHAT stock dropped 300m (30%) in MC due to a 10m dollar reduction in end of year guidance. Essentially a rounding error of <3% of thier expected sales in 2026.

1 · Reply

Joe_90_ Aug. 14 at 7:31 PM

$PHAT Folks, see the gap that needs to be filled, and the MACD signal about to cross :)

1 · Reply

fgggggggg Aug. 14 at 6:25 PM

$PHAT

0 · Reply

Valueforall Aug. 14 at 4:53 PM

$PHAT been adding any and all dips here. I seek full value for the fundamentals they deliver. That number is much higher than where this trades

0 · Reply

Morrito23 Aug. 14 at 3:26 PM

$PHAT our 13F’s continue to look very strong. Nasdaq now says we are at 93% institutional ownership. If my memory serves me right, we were at about 89% before earnings? Correct me if I’m wrong

1 · Reply

fgggggggg Aug. 14 at 2:05 PM

$PHAT

0 · Reply

ajmrtxl Aug. 14 at 11:12 AM

$PHAT 's latest data on SqueezeFinder

0 · Reply

Joe_90_ Aug. 13 at 11:05 PM

$PHAT latest update, Blackrock shareholding increased by 11.4%, Institutional Ownership now standing at 92.67%, anticipate further updates tomorrow

0 · Reply

fgggggggg Aug. 13 at 5:28 PM

$PHAT

0 · Reply

JuggernautRaider Aug. 13 at 1:33 PM

$PHAT $PHVS $PHAR are STRUGGLING! $ALT … of Morristown? Under CEO Jerry Durso? They are tightening up! ⬆️ 💪 🏃‍♂️ Back to school, children 👧

0 · Reply

StardustTrader Aug. 12 at 8:25 PM

$PHAT 1:10 candle lol. Someone forgot to layer the oder and smacked almost half a million shares 😅

3 · Reply

Ecryder Aug. 12 at 8:18 PM

$PHAT refreshing end of trade today

0 · Reply

Withermania Aug. 12 at 7:42 PM

$PHAT loading the boat in the $8 ish range will be the easiest money made. This team is on track and will beat their guidance. $330MM looking like the NET top line for 2026. Buyout in 2027as this cements itself as the standard of care in the GI space. Also, AI trade will fade and this will see major inflows

0 · Reply

Market Cap	750.76M
Revenue (ttm)	175.11M
Net Income (ttm)	-221.25M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-126.35%
Debt to Equity Ratio	-0.48

Volume	976,400
Avg Vol	1,330,308
Day's Range	N/A - N/A
Shares Out	80.90M
Stochastic %K	66%
Beta	0.51
Analysts	Strong Sell
Price Target	$21.50